Title
A Bioequivalence Study of Vinorelbine Tartrate Injectable Emulsion in Patients With Advanced Cancer.
A Bioequivalence Study of Vinorelbine Tartrate Injectable Emulsion (ANX-530) in Patients With Advanced Cancer.
Phase
Phase 1Lead Sponsor
Mast TherapeuticsStudy Type
InterventionalStatus
Completed Results PostedIndication/Condition
Breast Cancer Non-small Cell Lung Cancer Non-Hodgkins LymphomaIntervention/Treatment
vinorelbine ...Study Participants
31This study was a randomized, single dose crossover comparison of the investigational product with a Reference Product (vinorelbine tartrate injection, NAVELBINE®). The primary objective was to demonstrate the equivalence of ANX-530 and the Reference Product, NAVELBINE.
ANX-530 (vinorelbine tartrate injectable emulsion), an investigational drug, is an oil-in-water emulsion of vinorelbine tartrate composed of an oil phase and emulsifier dispersed in an aqueous solution. ADVENTRX Pharmaceuticals, Inc. of San Diego, California, developed ANX-530 as a vinorelbine tartrate formulation to be used in clinical settings where Vinorelbine Tartrate Injection (NAVELBINE) is indicated. Nonclinical toxicology studies suggest either equivalent or less toxicity of ANX-530 compared to Reference Product. In particular, ANX-530 caused less vein toxicity in a rabbit vein irritation model, suggesting ANX-530 could potentially cause less venous irritation than NAVELBINE in a clinical setting. ADVENTRX is investigating whether ANX-530 could substitute for NAVELBINE in these settings.
Subjects received one dose each of ANX-530 and NAVELBINE, each providing 30 mg/m2 vinorelbine. Study drugs will be infused into an arm vein over ten minutes.
Inclusion Criteria: Age > 18 years. Advanced cancer potentially sensitive to vinorelbine: Breast cancer. Stage 3 or 4 non-small cell lung cancer. Non-Hodgkins lymphoma. Cancer of other histologic type, sensitive to vinca alkaloids. Rare tumor type with no standard treatment, for which single agent vinorelbine is appropriate therapy. Failure of standard treatment(s) of the tumor. Life expectancy of at least three months. ECOG performance level 0-2 or Karnofsky score 100-70. Hematological and serum chemistry results with defined ranges. Willingness and ability to provide written informed consent. Exclusion Criteria: Pregnancy or lactation. In a woman of childbearing potential, a positive pregnancy test result, no pregnancy test result, or no use of reliable contraception, at baseline. A postmenopausal woman will be considered to be of childbearing potential until there has been amenorrhea for at least 12 consecutive months. Previous treatment with vinorelbine or mitomycin. Any history suggesting or demonstrating resistance to, lack of response to, or intolerance of any prior vinca alkaloid treatment. Active infection. Prior anticancer therapy completed within four weeks prior to the first day of study treatment. Failure to have recovered from any toxicity of previous cancer treatment (patients with alopecia will not be excluded). Participation in another experimental drug study within four weeks prior to the first day of study treatment. Requirement for any concomitant chemotherapeutic agent other than the study medication. Any investigator judgment that the individual would not be an appropriate study subject.
| Event Type | Organ System | Event Term | ANX-530/Navelbine | Navelbine/ANX-530 |
|---|
Estimated via linear regression of the time versus log concentration
t1/2 = [ln(2)/λ z]
Determined Using the Linear Trapezoidal Rule
AUCinf = AUClast + (Clast/lamda z)
MRT = (AUMCinf)/(AUCinf)
